Edgewise Therapeutics, Inc.
EWTX
Rank in Stocks
#4058
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Share Price
$37.19
Last synced: 2026-10-16
Market Cap
$4.00B
Change (1 day)
-2.64%
Change (1 year)
146.95%
Country
US
Trade Edgewise Therapeutics, Inc. (EWTX)
Category
Healthcare
Earnings for Edgewise Therapeutics, Inc. (EWTX)
Earnings in Jun 2026 TTM: $-197.22M
According to Edgewise Therapeutics, Inc. latest financial reports the company's current earnings are $-197.22M. In 2023 the company made an earning of $-100.16M, a decrease compared to its 2022 earnings that were of $-67.64M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Edgewise Therapeutics, Inc. from 2019 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-197.22M | 47.39% |
| 2024 | $-133.81M | 33.60% |
| 2023 | $-100.16M | 48.08% |
| 2022 | $-67.64M | 57.99% |
| 2021 | $-42.81M | 150.03% |
| 2020 | $-17.12M | 76.43% |
| 2019 | $-9.71M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -2,774.60% |
US
|
|
| $-3.09B | 1,465.24% |
US
|
|
| $-4.02B | 1,936.38% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,089.06% |
NL
|
